Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11669542 | 0.88 | TDP1 (0.47) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL29163865 | 0.87 | TDP1 (0.51) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL4849618 | 0.86 | TDP1 (0.55) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL304470 | 0.86 | CASP6 (0.55) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL3260821 | 0.85 | TDP1 (0.53) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL27501298 | 0.85 | CASP6 (0.53) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL9489755 | 0.81 | SELL (0.44) | TSHRTDP1L3MBTL1GPR35ALDH1A1 | |
| SCHEMBL15622 | 0.81 | DTYMK (0.49) | DTYMKTSHRTDP1CASP6GPR35 | |
| SCHEMBL20472291 | 0.81 | GPR35 (0.52) | DTYMKTSHRTDP1L3MBTL1CASP6 | |
| SCHEMBL6536440 | 0.80 | TSHR (0.46) | DTYMKTSHRTDP1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903431-A | Carbon nano tube composite material and preparation method and application thereof | 浙江王点科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| JP-55136246-A | — | — | None | — | — | JP | disclosed |
| CN-117903431-A | Carbon nano tube composite material and preparation method and application thereof | 浙江王点科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-9869027-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| US-20160230289-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9340759-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-17 | — | — | US | disclosed |
| US-RE45685-E1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150136728-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| EP-1228071-B8 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2263669-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2255801-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7678825-B2 | Pharmaceutically active isoindoline derivates | CELGENE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| EP-1698334-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| JP-S55136246-A | PREPARATION OF HYDROXY-DI-PHTHALIC ACID | MITSUI TOATSU CHEM INC | 1980-10-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | PDE3A, PDE2A, PDE5A | DTYMK 368/4885TSHR 4476/4885TDP1 27/4885 |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | DTYMK 304/4885TSHR 4087/4885TDP1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.